SWAV Stock Overview
A medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Shockwave Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$334.75 |
| 52 Week High | US$334.90 |
| 52 Week Low | US$157.00 |
| Beta | 0.88 |
| 1 Month Change | 1.49% |
| 3 Month Change | 27.08% |
| 1 Year Change | 15.77% |
| 3 Year Change | 97.43% |
| 5 Year Change | 432.11% |
| Change since IPO | 997.54% |
Recent News & Updates
Recent updates
Shockwave Medical, Inc.'s (NASDAQ:SWAV) 28% Jump Shows Its Popularity With Investors
Apr 06
Is Now An Opportune Moment To Examine Shockwave Medical, Inc. (NASDAQ:SWAV)?
Mar 24Shockwave Medical: Opening Arteries, Delivering Returns
Feb 28Shockwave Medical, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Feb 18There's Been No Shortage Of Growth Recently For Shockwave Medical's (NASDAQ:SWAV) Returns On Capital
Feb 06Calculating The Fair Value Of Shockwave Medical, Inc. (NASDAQ:SWAV)
Jan 24Some Shareholders Feeling Restless Over Shockwave Medical, Inc.'s (NASDAQ:SWAV) P/E Ratio
Jan 09Is Shockwave Medical (NASDAQ:SWAV) A Risky Investment?
Dec 27Shareholder Returns
| SWAV | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.2% | -3.4% | -3.5% |
| 1Y | 15.8% | 9.0% | 22.1% |
Return vs Industry: SWAV exceeded the US Medical Equipment industry which returned 3.8% over the past year.
Return vs Market: SWAV underperformed the US Market which returned 25.2% over the past year.
Price Volatility
| SWAV volatility | |
|---|---|
| SWAV Average Weekly Movement | 3.6% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SWAV has not had significant price volatility in the past 3 months.
Volatility Over Time: SWAV's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,468 | Doug Godshall | shockwavemedical.com |
Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina.
Shockwave Medical, Inc. Fundamentals Summary
| SWAV fundamental statistics | |
|---|---|
| Market cap | US$12.57b |
| Earnings (TTM) | US$163.50m |
| Revenue (TTM) | US$787.97m |
76.9x
P/E Ratio15.9x
P/S RatioIs SWAV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SWAV income statement (TTM) | |
|---|---|
| Revenue | US$787.97m |
| Cost of Revenue | US$102.53m |
| Gross Profit | US$685.44m |
| Other Expenses | US$521.94m |
| Earnings | US$163.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 05, 2024
| Earnings per share (EPS) | 4.35 |
| Gross Margin | 86.99% |
| Net Profit Margin | 20.75% |
| Debt/Equity Ratio | 97.5% |
How did SWAV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/31 22:23 |
| End of Day Share Price | 2024/05/30 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shockwave Medical, Inc. is covered by 12 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| William Plovanic | Canaccord Genuity |
| Kristen Stewart | CL King & Associates, Inc. |